Eli Lilly announced Wednesday that its weight loss therapy, tirzepatide, reached main goals in two Phase 3 trials for patients with obesity and obstructive sleep apnea (OSA), a sleep-related breathing...
Source LinkEli Lilly announced Wednesday that its weight loss therapy, tirzepatide, reached main goals in two Phase 3 trials for patients with obesity and obstructive sleep apnea (OSA), a sleep-related breathing...
Source Link
Comments